Touchlight has added new circular DNA architectures for advanced therapies
Touchlight, specialists in cell-free DNA technology, is expanding its mbDNA platform with the addition of three new circular DNA architectures: sscDNA, hsscDNA, and dscDNA.
These constructs join mbDNA to form a comprehensive portfolio that addresses the limitations of traditional gene-editing tools.
The mbDNA platform and new custom circle DNA architectures can provide stability, decreased immunogenicity, and compatibility with a wide range of gene-insertion and expression technologies.
mbDNA is a single-stranded DNA technology produced through Touchlight’s cell-free enzymatic platform, delivering high purity and minimal immunogenicity for safer outcomes, and enabling enzymatic production for optimal reliability and scalability. It can achieve high HDR efficiency with low toxicity and reach knock-in rates of 60-75% in primary T cells, while also offering predictable performance with low donor-donor variability. In addition, mbDNA supports an expanded payload capacity of up to 20kb, allowing for large genetic cargoes and new possibilities for advanced gene editing.
Touchlight’s novel circular DNA molecules are flexible, enabling bespoke designs to optimise gene therapy platforms that use DNA payloads for episomal expression or integration. sscDNA is a fully single-stranded circular DNA molecule, hsscDNA contains bespoke double-stranded region(s) of user-defined length, and dscDNA is a fully double-stranded circular molecule.
Karen Fallen, CEO at Touchlight, said, “mbDNA is a market-leading technology providing the best-in-class HDR template available today. With the addition of sscDNA, hsscDNA, and dscDNA, we’re empowering researchers and developers to unlock new possibilities in gene editing and therapeutic innovation.”
